

Executive Summary

Evaluating Workplace Drug Testing Effectiveness:

A System Sensitivity Perspective on Urine vs. Oral Fluid Testing

Jim Tedrow, MT(ASCP)

The Compliance Resource Group, Inc.

1. The Core Insight

Workplace drug testing has historically been evaluated primarily through a laboratory-based lens—focused on analytical sensitivity, cutoffs, and assay performance.

This paper demonstrates that real-world effectiveness is not determined at the lab—it is determined at the system level.

Key Distinction:

- Analytical Sensitivity → Can the lab detect drugs in a valid specimen?
- System Sensitivity → Does the testing *system* actually capture drug use in real-world conditions?

Conclusion:

Two testing methods with similar analytical performance can produce materially different real-world outcomes due to differences in collection design, donor behavior, and specimen integrity.

2. What the Data Shows (Across Multiple Data Sources)

This analysis integrates four independent data sources:

- 2 program-level transitions (urine → oral fluid)
- Contemporaneous paired DOT urine and non-DOT oral fluid testing (same donors, same time)
- National dataset (Quest Drug Testing Index)

Consistent Finding:


Across all three sources, the direction and magnitude of the effect are consistent—oral fluid testing identifies materially more illicit drug use under comparable conditions.

3. Real-World Detection Differences


Program-level Transition Data: *Employers in unrelated industries transitioned from urine to oral fluid in pre-employment testing programs.*

- Warehouse: 4.6% → 15.1% positivity (**~3.3x increase**)
- Hospital: 2.16% → 5.68% (**~2.6x increase**)

Warehouse Case Study




Hospital Case Study



Contemporaneous Paired Testing: *DOT urine and employer mandated non-DOT oral fluid test performed on same donors at same time.*

- DOT Urine: 2.04%
- Oral Fluid: 7.14% (**~3.5x higher**)
- Oral fluid identified **6x more discordant positives** in the same population (12:2)



Because these samples were collected from the same donors at the same time, this difference cannot be explained by population or timing—it reflects the testing system itself.


National Data: Quest Drug Testing Index (DTI)

Includes aggregated data of ~25-30M urine tests and ~6-8M oral fluid tests included in the 2025 DTI (2020-24 DTI reporting period).

Relative System Sensitivity: Comparison of aggregated positive rates between matrices within individual drug categories.


Calculated as: $\text{Relative System Sensitivity} = \text{Oral Fluid Positive Rate} \div \text{Urine Positive rate}$

<u>Illicit Drug Categories</u>	<u>Detection Ratio (OF:Urine)</u>
Marijuana	2.78 : 1
Cocaine	3.78 : 1
PCP	4.71 : 1
Methamphetamine	5.14 : 1



When compared with oral fluid, DTI data suggests that for every instance of illicit drug use identified in urine, ~2 to 4 may be missed

<u>Rx Tolerant Drug Categories</u>	<u>Detection Ratio (OF:Urine)</u>
Amphetamine	0.66 : 1
Opioids	0.59 : 1



Drug categories associated with legitimate prescription use show substantially smaller divergence. In scenarios where incentive to evade detection is minimized, longer detection window associated with urine may produce equal or higher positivity rates.

4. Why This Happens (Not a Lab Issue)

The difference is not analytical—it is behavioral and structural.

Urine Testing Environment:

- Privacy during collection
- Limited observation
- Donor control over specimen
- Opportunity for circumvention

Oral Fluid Testing Environment:

- Direct observation
- Continuous line-of-sight
- Immediate donor-specimen linkage

Result:

Oral fluid testing more consistently captures an authentic specimen from the intended donor at the time of testing.

5. The Behavioral Pattern That Explains Everything

Detection differences follow incentives, not chemistry.

Illicit Drugs (High Consequence)

- Consequences of positive test are unavoidable
- Strong incentive to evade detection
- Largest detection gaps
- Oral fluid: **2–5x higher detection**

Prescription Drugs (Reduced Consequence with valid Rx)

- Legitimate explanations available (MRO)
- Minimal incentive to evade
- Urine circumvention is reduced

Interpretation:

Testing systems don't just measure drug use—they interact with human behavior.

6. The Industry Blind Spot

Most stakeholders:

- See reported positives
- Do not see missed positives

This creates a **critical distortion**: Employers often overestimate the effectiveness of urine testing because undetected drug use is invisible – operate under an assumed that urine testing programs are performing adequately.

7. If the Data Is Clear—Why Hasn't Adoption Followed?

Adoption is not limited by science - it is limited by system friction.

Key Barriers:

- Limited performance transparency obscures true system-level value for employers
- Inventory risk (collection sites must pre-purchase devices)
- Misaligned economics (cost occurs before revenue)
- Lack of device tracking visibility
- Fragmented responsibility across stakeholders

These are structural—not technical—constraints.

8. What the Market Is Missing

The ecosystem does not currently operate with:


- Clear visibility into relative system-level performance
- End-to-end tracking of the device lifecycle
- Alignment between cost and utilization
- Incentives tied to actual detection effectiveness

Without these, adoption defaults to:

Lower cost + familiarity (urine)

instead of

Higher effectiveness + better value (oral fluid)



9. What a Scalable Solution Requires

A viable oral fluid model must introduce coordination across:

1. Visibility: Track devices from shipment → collection → lab
2. Economic Alignment: Improve cost and revenue event timing
3. Risk Distribution: Align risk with those who control outcomes
4. Operational Simplicity: No added burden to collection sites or labs
5. Coordinating Layer: Connect stakeholders without replacing them

10. Why This Matters

This is more than a discussion about test options—it is a structural market inefficiency with measurable performance consequences.

Current State:

- A less effective detection system (urine) remains dominant
- Better-performing system (oral fluid) underutilized

Reason:

- Limited visibility into system-level performance
- Misaligned incentives and economic timing

What Is Required: A Coordinated System That:

- Improves visibility
- Aligns economics
- Reduces friction


What This Unlocks:

- Increased adoption
- Expanded market demand
- Higher detection effectiveness and risk reduction

When system-level performance is visible and structural barriers are removed, migration toward the more effective testing model is not speculative—it is the logical outcome.

Full methodology, dataset descriptions, and supporting analysis are included in the complete white paper.

Access the full paper:



Author Contact:

jtedrow@thecrginc.com